Outcomes in patients with cardiac amyloidosis undergoing heart transplantation: the eurotransplant experience

Background - When advanced heart failure occurs in cardiac amyloidosis, prognosis is poor. In this setting heart transplantation (HTX) is a treatment option for selected patients. We here present the results of post-transplantation outcomes in cardiac amyloidosis within the Eurotransplant area, inve...

Full description

Saved in:
Bibliographic Details
Main Authors: Volz, Martin J. (Author) , Smits, Jacqueline M. (Author) , Meyer, Anna L. (Author) , Strelniece, Agita (Author) , van Kins, Arne (Author) , Boeken, Udo (Author) , Reinecke, Alexander (Author) , Provaznik, Zdenek (Author) , Van Caenegem, Oliver (Author) , Ancion, Arnaud (Author) , Berchtold-Herz, Michael (Author) , Van Cleemput, Johan J. A. (Author) , Haverich, Axel (Author) , Laufer, Guenther (Author) , Gummert, Jan (Author) , Karck, Matthias (Author) , Warnecke, Gregor (Author) , Raake, Philip (Author) , Frey, Norbert (Author) , Kreußer, Michael (Author)
Format: Article (Journal)
Language:English
Published: June 2023
In: The journal of heart and lung transplantation
Year: 2023, Volume: 42, Issue: 6, Pages: 778-785
ISSN:1557-3117
DOI:10.1016/j.healun.2023.01.001
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.healun.2023.01.001
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1053249823000013
Get full text
Author Notes:Martin J. Kraus, Jacqueline M. Smits, Anna L. Meyer, Agita Strelniece, Arne van Kins, Udo Boeken, Alexander Reinecke, Zdenek Provaznik, Oliver Van Caenegem, Arnaud Ancion, Michael Berchtold-Herz, Johan J.A. Van Cleemput, Axel Haverich, Guenther Laufer, Jan Gummert, Matthias Karck, Gregor Warnecke, Philip W. Raake, Norbert Frey, and Michael M. Kreusser

MARC

LEADER 00000caa a2200000 c 4500
001 1856211630
003 DE-627
005 20240329080237.0
007 cr uuu---uuuuu
008 230815s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.healun.2023.01.001  |2 doi 
035 |a (DE-627)1856211630 
035 |a (DE-599)KXP1856211630 
035 |a (OCoLC)1425212976 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Volz, Martin J.  |d 1991-  |e VerfasserIn  |0 (DE-588)1221647512  |0 (DE-627)1738963454  |4 aut 
245 1 0 |a Outcomes in patients with cardiac amyloidosis undergoing heart transplantation  |b the eurotransplant experience  |c Martin J. Kraus, Jacqueline M. Smits, Anna L. Meyer, Agita Strelniece, Arne van Kins, Udo Boeken, Alexander Reinecke, Zdenek Provaznik, Oliver Van Caenegem, Arnaud Ancion, Michael Berchtold-Herz, Johan J.A. Van Cleemput, Axel Haverich, Guenther Laufer, Jan Gummert, Matthias Karck, Gregor Warnecke, Philip W. Raake, Norbert Frey, and Michael M. Kreusser 
264 1 |c June 2023 
300 |b Illustrationen 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online verfügbar: 12. Januar 2023, Artikelversion: 15. Mai 2023 
500 |a Gesehen am 15.08.2023 
520 |a Background - When advanced heart failure occurs in cardiac amyloidosis, prognosis is poor. In this setting heart transplantation (HTX) is a treatment option for selected patients. We here present the results of post-transplantation outcomes in cardiac amyloidosis within the Eurotransplant area, investigating possible predictors of survival. - Methods - Of 115 patients undergoing HTX due to cardiac amyloidosis in the Eurotransplant region between November 1987 and May 2020, detailed assessment prior to transplantation was available in 85 patients. The present study was conducted in a retrospective approach. Primary endpoint was mortality after HTX. Baseline variables were entered in a Cox proportional hazards model with the primary endpoint as a dependent variable. - Results - Median overall survival following HTX was 6.3 years in the overall collective and the subgroup. Univariate Cox proportional hazards model revealed a significant relationship between overall survival and the transplantation period (2008 to 2020 vs 1987 to 2007; median survival 9.7 years vs 1.8 years, hazard ratio 0.45, p = 0.01). Further predictors were albumin concentration (hazard ratio 0.92, p < 0.001), and systolic blood pressure (hazard ratio 0.96, p < 0.001). The transplant period as well as albumin concentration remained significant independent predictors in the AL sub cohort in a multivariate Cox proportional hazards model. - Conclusions - HTX is a viable treatment option for patients at an advanced stage of cardiac amyloidosis as overall survival after transplantation has improved in the modern age. Patients at a very advanced stage of the disease, indicated by low serum albumin and blood pressure, show worse outcomes following HTX. Optimal timing and careful patient selection may therefore be particularly important to further improve post-HTX survival in amyloidosis patients. 
700 1 |a Smits, Jacqueline M.  |e VerfasserIn  |4 aut 
700 1 |a Meyer, Anna L.  |d 1977-  |e VerfasserIn  |0 (DE-588)130213896  |0 (DE-627)495058912  |0 (DE-576)298066866  |4 aut 
700 1 |a Strelniece, Agita  |e VerfasserIn  |4 aut 
700 1 |a van Kins, Arne  |e VerfasserIn  |4 aut 
700 1 |a Boeken, Udo  |e VerfasserIn  |4 aut 
700 1 |a Reinecke, Alexander  |e VerfasserIn  |4 aut 
700 1 |a Provaznik, Zdenek  |e VerfasserIn  |4 aut 
700 1 |a Van Caenegem, Oliver  |e VerfasserIn  |4 aut 
700 1 |a Ancion, Arnaud  |e VerfasserIn  |4 aut 
700 1 |a Berchtold-Herz, Michael  |e VerfasserIn  |4 aut 
700 1 |a Van Cleemput, Johan J. A.  |e VerfasserIn  |4 aut 
700 1 |a Haverich, Axel  |e VerfasserIn  |4 aut 
700 1 |a Laufer, Guenther  |e VerfasserIn  |4 aut 
700 1 |a Gummert, Jan  |e VerfasserIn  |4 aut 
700 1 |a Karck, Matthias  |d 1961-  |e VerfasserIn  |0 (DE-588)130833525  |0 (DE-627)505909340  |0 (DE-576)298366169  |4 aut 
700 1 |a Warnecke, Gregor  |d 1974-  |e VerfasserIn  |0 (DE-588)125001517  |0 (DE-627)370699629  |0 (DE-576)294612823  |4 aut 
700 1 |a Raake, Philip  |d 1975-  |e VerfasserIn  |0 (DE-588)129151246  |0 (DE-627)390021725  |0 (DE-576)297510568  |4 aut 
700 1 |a Frey, Norbert  |e VerfasserIn  |0 (DE-588)141244976  |0 (DE-627)625824075  |0 (DE-576)322969514  |4 aut 
700 1 |a Kreußer, Michael  |d 1980-  |e VerfasserIn  |0 (DE-588)132382385  |0 (DE-627)521949424  |0 (DE-576)260798495  |4 aut 
773 0 8 |i Enthalten in  |t The journal of heart and lung transplantation  |d Amsterdam [u.a.] : Elsevier Science, 1999  |g 42(2023), 6 vom: Juni, Seite 778-785  |h Online-Ressource  |w (DE-627)306659743  |w (DE-600)1500494-6  |w (DE-576)260773786  |x 1557-3117  |7 nnas  |a Outcomes in patients with cardiac amyloidosis undergoing heart transplantation the eurotransplant experience 
773 1 8 |g volume:42  |g year:2023  |g number:6  |g month:06  |g pages:778-785  |g extent:8  |a Outcomes in patients with cardiac amyloidosis undergoing heart transplantation the eurotransplant experience 
856 4 0 |u https://doi.org/10.1016/j.healun.2023.01.001  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S1053249823000013  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20230815 
993 |a Article 
994 |a 2023 
998 |g 132382385  |a Kreußer, Michael  |m 132382385:Kreußer, Michael  |d 50000  |e 50000PK132382385  |k 0/50000/  |p 20  |y j 
998 |g 141244976  |a Frey, Norbert  |m 141244976:Frey, Norbert  |d 910000  |d 910100  |e 910000PF141244976  |e 910100PF141244976  |k 0/910000/  |k 1/910000/910100/  |p 19 
998 |g 129151246  |a Raake, Philip  |m 129151246:Raake, Philip  |d 910000  |d 910100  |d 50000  |e 910000PR129151246  |e 910100PR129151246  |e 50000PR129151246  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 18 
998 |g 125001517  |a Warnecke, Gregor  |m 125001517:Warnecke, Gregor  |d 910000  |d 910200  |e 910000PW125001517  |e 910200PW125001517  |k 0/910000/  |k 1/910000/910200/  |p 17 
998 |g 130833525  |a Karck, Matthias  |m 130833525:Karck, Matthias  |d 910000  |d 910200  |e 910000PK130833525  |e 910200PK130833525  |k 0/910000/  |k 1/910000/910200/  |p 16 
998 |g 130213896  |a Meyer, Anna L.  |m 130213896:Meyer, Anna L.  |d 910000  |d 910200  |e 910000PM130213896  |e 910200PM130213896  |k 0/910000/  |k 1/910000/910200/  |p 3 
998 |g 1221647512  |a Volz, Martin J.  |m 1221647512:Volz, Martin J.  |d 910000  |d 910100  |e 910000PV1221647512  |e 910100PV1221647512  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1856211630  |e 4366346958 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"origin":[{"publisherPlace":"Amsterdam [u.a.]","dateIssuedDisp":"[1999?]-","publisher":"Elsevier Science"}],"title":[{"title":"The journal of heart and lung transplantation","subtitle":"a forum that includes basic science, the failing heart, and advanced lung disease ; the official publication of the International Society for Heart and Lung Transplantation","title_sort":"journal of heart and lung transplantation"}],"id":{"issn":["1557-3117"],"eki":["306659743"],"zdb":["1500494-6"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"306659743","disp":"Outcomes in patients with cardiac amyloidosis undergoing heart transplantation the eurotransplant experienceThe journal of heart and lung transplantation","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["Nachgewiesen 18.1999 -"],"note":["Gesehen am 15.01.20","Ungezählte Beil.: Supplement"],"language":["eng"],"part":{"text":"42(2023), 6 vom: Juni, Seite 778-785","extent":"8","pages":"778-785","issue":"6","year":"2023","volume":"42"}}],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"June 2023"}],"title":[{"title":"Outcomes in patients with cardiac amyloidosis undergoing heart transplantation","subtitle":"the eurotransplant experience","title_sort":"Outcomes in patients with cardiac amyloidosis undergoing heart transplantation"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1856211630"],"doi":["10.1016/j.healun.2023.01.001"]},"physDesc":[{"noteIll":"Illustrationen","extent":"8 S."}],"recId":"1856211630","person":[{"display":"Volz, Martin J.","given":"Martin J.","family":"Volz","role":"aut"},{"display":"Smits, Jacqueline M.","given":"Jacqueline M.","family":"Smits","role":"aut"},{"role":"aut","family":"Meyer","display":"Meyer, Anna L.","given":"Anna L."},{"role":"aut","family":"Strelniece","given":"Agita","display":"Strelniece, Agita"},{"role":"aut","family":"van Kins","given":"Arne","display":"van Kins, Arne"},{"family":"Boeken","role":"aut","display":"Boeken, Udo","given":"Udo"},{"family":"Reinecke","role":"aut","given":"Alexander","display":"Reinecke, Alexander"},{"role":"aut","family":"Provaznik","given":"Zdenek","display":"Provaznik, Zdenek"},{"role":"aut","family":"Van Caenegem","display":"Van Caenegem, Oliver","given":"Oliver"},{"given":"Arnaud","display":"Ancion, Arnaud","role":"aut","family":"Ancion"},{"role":"aut","family":"Berchtold-Herz","given":"Michael","display":"Berchtold-Herz, Michael"},{"role":"aut","family":"Van Cleemput","display":"Van Cleemput, Johan J. A.","given":"Johan J. A."},{"family":"Haverich","role":"aut","display":"Haverich, Axel","given":"Axel"},{"role":"aut","family":"Laufer","given":"Guenther","display":"Laufer, Guenther"},{"given":"Jan","display":"Gummert, Jan","role":"aut","family":"Gummert"},{"role":"aut","family":"Karck","given":"Matthias","display":"Karck, Matthias"},{"given":"Gregor","display":"Warnecke, Gregor","family":"Warnecke","role":"aut"},{"role":"aut","family":"Raake","given":"Philip","display":"Raake, Philip"},{"given":"Norbert","display":"Frey, Norbert","family":"Frey","role":"aut"},{"given":"Michael","display":"Kreußer, Michael","role":"aut","family":"Kreußer"}],"note":["Online verfügbar: 12. Januar 2023, Artikelversion: 15. Mai 2023","Gesehen am 15.08.2023"],"language":["eng"],"name":{"displayForm":["Martin J. Kraus, Jacqueline M. Smits, Anna L. Meyer, Agita Strelniece, Arne van Kins, Udo Boeken, Alexander Reinecke, Zdenek Provaznik, Oliver Van Caenegem, Arnaud Ancion, Michael Berchtold-Herz, Johan J.A. Van Cleemput, Axel Haverich, Guenther Laufer, Jan Gummert, Matthias Karck, Gregor Warnecke, Philip W. Raake, Norbert Frey, and Michael M. Kreusser"]}} 
SRT |a VOLZMARTINOUTCOMESIN2023